{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:32:45Z","timestamp":1790253165346,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001962","name":"World Anti-Doping Agency","doi-asserted-by":"publisher","award":["18B04AM"],"award-info":[{"award-number":["18B04AM"]}],"id":[{"id":"10.13039\/501100001962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jpba.2020.113750","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T17:25:50Z","timestamp":1604597150000},"page":"113750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Evaluation of erythropoietin biosimilars Epotin\u2122, Hemax\u00ae and Jimaixin\u2122 by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex\u00ae"],"prefix":"10.1016","volume":"194","author":[{"given":"Perrine","family":"Capdeville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cholet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelaure","family":"Damont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Audran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Fenaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113750_bib0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/ndt\/gfu089","article-title":"The ESA scenario gets complex: from biosimilar epoetins to activin traps","volume":"30","author":"Jelkmann","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jpba.2020.113750_bib0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2215\/CJN.01980218","article-title":"Biosimilars-emerging role in nephrology","volume":"14","author":"Wish","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jpba.2020.113750_bib0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/glycob\/cwp079","article-title":"Optimal and consistent protein glycosylation in mammalian cell culture","volume":"19","author":"Hossler","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.jpba.2020.113750_bib0020","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1021\/acs.analchem.7b00353","article-title":"Analysis of three epoetin alpha products by LC and LC-MS indicates differences in glycosylation critical quality attributes, including sialic acid content","volume":"89","author":"Thomson","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2020.113750_bib0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/07388551.2017.1416577","article-title":"Impact of host cell line choice on glycan profile","volume":"38","author":"Goh","year":"2018","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jpba.2020.113750_bib0030","doi-asserted-by":"crossref","first-page":"14524","DOI":"10.1021\/bi0265022","article-title":"Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions","volume":"41","author":"Darling","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.jpba.2020.113750_bib0035","series-title":"Harmonization of Analysis and Reporting of Erythropoiesis Stimulating Agents (ESAs) by Electrophoretic Techniques","author":"TD2014EPO","year":"2014"},{"key":"10.1016\/j.jpba.2020.113750_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trac.2015.04.024","article-title":"Mass spectrometry for glycosylation analysis of biopharmaceuticals","volume":"73","author":"Dotz","year":"2015","journal-title":"Trends Analyt. Chem."},{"key":"10.1016\/j.jpba.2020.113750_bib0045","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1038\/s41598-017-05641-1","article-title":"Affinity purification of erythropoietin from cell culture supernatant combined with MALDI-TOF-MS analysis of erythropoietin N-glycosylation","volume":"7","author":"Falck","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2020.113750_bib0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4939-4014-1_13","article-title":"Capillary electrophoresis method for the assessment of erythropoiesis-stimulating agents in final formulations","volume":"1466","author":"Girard","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jpba.2020.113750_bib0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.trac.2015.02.004","article-title":"Technologies for glycomic characterization of biopharmaceutical erythropoietins","volume":"68","author":"Hua","year":"2015","journal-title":"Trends Analyt. Chem."},{"key":"10.1016\/j.jpba.2020.113750_bib0060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4155\/bio.16.20","article-title":"Analytical detection and characterization of biopharmaceutical glycosylation by MS","volume":"8","author":"Oh","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2020.113750_bib0065","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1021\/acs.analchem.6b01639","article-title":"Automated high-throughput permethylation for glycosylation analysis of biologics using MALDI-TOF-MS","volume":"88","author":"Shubhakar","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2020.113750_bib0070","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1021\/acs.analchem.5b00758","article-title":"Rapid Preparation of Released N-Glycans for HILIC Analysis Using a Labeling Reagent that Facilitates Sensitive Fluorescence and ESI-MS Detection","volume":"87","author":"Lauber","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2020.113750_bib0075","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/dta.2185","article-title":"Report on an anti-doping operation in Guadeloupe: high number of positive cases and inferences about doping habits","volume":"9","author":"Marchand","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2020.113750_bib0080","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/dta.2004","article-title":"New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration","volume":"8","author":"Martin","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2020.113750_bib0085","doi-asserted-by":"crossref","unstructured":"L. Martin, J. Martin, D. Collot, O. Hoang, M. Audran, M. Ericsson, A. Marchand, Improved detection methods significantly increase the detection window for EPO microdoses, Drug Test Anal, in press (2020).","DOI":"10.1002\/dta.2904"},{"key":"10.1016\/j.jpba.2020.113750_bib0090","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/elps.201800021","article-title":"Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation","volume":"39","author":"Bruneel","year":"2018","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2020.113750_bib0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/rcm.7125","article-title":"Evaluation of a combined glycomics and glycoproteomics approach for studying the major glycoproteins present in biofluids: application to cerebrospinal fluid","volume":"29","author":"Goyallon","year":"2015","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2020.113750_bib0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jpba.2018.02.043","article-title":"Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan","volume":"153","author":"Cowper","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113750_bib0105","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1021\/acs.jproteome.7b00862","article-title":"High performance anion exchange and hydrophilic interaction liquid chromatography approaches for comprehensive mass spectrometry-based characterization of the N-Glycome of a recombinant human erythropoietin","volume":"17","author":"Szabo","year":"2018","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jpba.2020.113750_bib0110","series-title":"Characterization of EPO N-Glycans Using RapiFluor-MS and HILIC Profiling","author":"Prasanna","year":"2015"},{"key":"10.1016\/j.jpba.2020.113750_bib0115","doi-asserted-by":"crossref","DOI":"10.3390\/nu11030528","article-title":"Comprehensive preterm breast milk metabotype associated with optimal infant early growth pattern","volume":"11","author":"Alexandre-Gouabau","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jpba.2020.113750_bib0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpba.2013.04.031","article-title":"Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC\/ESI-MS","volume":"83","author":"Harazono","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113750_bib0125","doi-asserted-by":"crossref","first-page":"46206","DOI":"10.1038\/srep46206","article-title":"Characterization of O-acetylation in sialoglycans by MALDI-MS using a combination of methylamidation and permethylation","volume":"7","author":"Wu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2020.113750_bib0130","series-title":"Recombinant Albumin Facilitates Formulation Design of Stable Drug Products in, Recombinant Albumin Facilitates Formulation Design of Stable Drug Products","author":"Perkins","year":"2012"},{"key":"10.1016\/j.jpba.2020.113750_bib0135","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4155\/bio-2017-0085","article-title":"Sensitive and comprehensive analysis of O-glycosylation in biotherapeutics: a case study of novel erythropoiesis stimulating protein","volume":"9","author":"Kim","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2020.113750_bib0140","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/dta.1563","article-title":"Differences in sialic acid O-acetylation between human urinary and recombinant erythropoietins: a possible mass spectrometric marker for doping control","volume":"5","author":"Reichel","year":"2013","journal-title":"Drug Test. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708520316368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708520316368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:08:51Z","timestamp":1760000931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708520316368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":28,"alternative-id":["S0731708520316368"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113750","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of erythropoietin biosimilars Epotin\u2122, Hemax\u00ae and Jimaixin\u2122 by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex\u00ae","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113750"}}